Analysts’ Recent Ratings Updates for Dyne Therapeutics (DYN)

A number of research firms have changed their ratings and price targets for Dyne Therapeutics (NASDAQ: DYN):

• 5/16/2026 – Dyne Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/15/2026 – Dyne Therapeutics was given a new $33.00 price target by Evercore Inc.
• 5/13/2026 – Dyne Therapeutics had its price target raised by Sanford C. Bernstein from $23.00 to $24.00. They now have a “market perform” rating on the stock.
• 5/2/2026 – Dyne Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/20/2026 – Dyne Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Dyne Therapeutics

In other news, Director Jason P. Rhodes sold 287,956 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $19.68, for a total value of $5,666,974.08. Following the transaction, the director owned 11,663 shares of the company’s stock, valued at $229,527.84. This represents a 96.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,559,462 shares of company stock worth $29,814,746. 20.77% of the stock is currently owned by corporate insiders.

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.